Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Japanese encephalitis chimeric virus vaccine (JE-CV)
Japanese encephalitis chimeric virus vaccine · 1 trial · 2 indications
Immunogenicity was assessed by the JE-CV virus and the SA14-14-2 virus 50% plaque reduction neutralization test (PRNT50). Japanese Encephalitis seroconversion was defined as a pre-vaccination titer \<10 1/dil and post-vaccination titer ≥ 10 1/dil; or a pre-vaccination titer ≥ 10 1/dil and a 4-fold increase from pre- to post-vaccination.
| Arm | Type | Description |
|---|---|---|
| JE-CV Group | EXPERIMENTAL | Participants will receive one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) |
| SA14-14-2 vaccine Group | ACTIVE_COMPARATOR | Participants will receive one dose of Japanese encephalitis live vaccine, SA14-14-2 vaccine. (CD.JEVAX®) |
| Name | Type | Description |
|---|---|---|
| Japanese encephalitis chimeric virus vaccine (JE-CV) | BIOLOGICAL | 0.5 mL, Subcutaneous |
| Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®) | BIOLOGICAL | 0.5 mL, Subcutaneous |
Inclusion Criteria : * Aged 9 to 18 months on the day of inclusion * In good general health, without significant medical history * Provision of informed consent form signed by at least one parent or other legally acceptable representative, and by at least one independent witness if required by loca...